Haystack MRD test detects minimal residual disease in stage 2 colorectal cancer patients post-surgery, using circulating tumor DNA (ctDNA) for less invasive monitoring. The FDA's breakthrough device ...

Circulating tumor DNA (ctDNA)—genetic material shed from tumors into the bloodstream—may help risk-stratify patients with Stage 3 colon cancer by tailoring chemotherapy options after surgery based on ...

A structured exercise program post-treatment improved disease-free and overall survival in stage 3 and high-risk stage 2 colorectal cancer patients. Patients in the exercise program had a 28% lower ...

Meta analysis in obese colorectal cancer patients found robotic assisted surgery modestly reduced hospital stay versus ...

While there are several treatment options for colon cancer, not all of them work for all cancer types. Deficient mismatch repair (dMMR) colon cancer is known to be less responsive to chemotherapy than ...

Colonic stent placement as a bridge to surgery shows similar survival to emergency resection while reducing stoma rates in obstructive colorectal cancer.

ROCHESTER, Minn. — Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating ...